Syndax (SNDX) announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a menin inhibitor, in patients with relapsed or refractory mutant NPM1 acute myeloid leukemia have been published in Blood.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax Pharmaceuticals’ Optimistic Q1 2025 Earnings Call
- Syndax price target raised to $17 from $16 at Scotiabank
- Syndax price target raised to $26 from $25 at BofA
- Promising Growth and Strategic Positioning Drive Buy Rating for Syndax Pharmaceuticals
- Syndax Pharmaceuticals Reports Strong Q1 2025 Results